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ABSTRACT 
 
 
Background  Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial 
recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved 
functional outcome. The impact of oral anticoagulants on endogenous fibrinolysis is 
unknown.  
Objective Our aim was to test the hypothesis that apixaban enhances endogenous fibrinolysis 
in non-valvular AF (NVAF).  
Methods  In a prospective cross-sectional analysis, we compared endogenous fibrinolysis in 
NVAF patients (n=180) taking aspirin, warfarin or apixaban. In a prospective longitudinal 
study, patients were tested before and after apixaban (n=80).  Endogenous fibrinolysis was 
assessed using the Global Thrombosis Test (GTT) and Thromboelastography (TEG). 
Results  Endogenous fibrinolysis (measured by GTT lysis time [LT]) was shorter on apixaban 
compared to warfarin or aspirin (median 1850[IQR 1591-2300] vs. 2758[2014-3502] vs. 
2135[1752-2463] sec, p<0.0001). Among TEG indices, a small but significant difference in 
clot lysis time (CLT) was observed (apixaban 60.0[45.0-61.0] vs. warfarin 61.0[57.0-62.0] 
vs. aspirin 61.0[59.0-61.0] min, p=0.036). Apixaban improved endogenous fibrinolysis 
measured using the GTT (LT pre-treatment 2204[1779-2738] vs. on-treatment 1882[1607-
2374] sec, p=0.0003), but not by using TEG. Change in LT (DLT) with apixaban correlated 
with baseline LT (r=0.77, p<0.0001). There was weak correlation between DLT and DCLT in 
response to apixaban (r=0.28, p=0.02) and between on-apixaban LT and CLT (r=0.25, 
p=0.022). 
Conclusions  Apixaban enhances endogenous fibrinolysis, with maximal effect in those with 
impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable 
fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer 
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additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared 
to warfarin, merits further study. 
 
Word count 248 
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Introduction 
 
Spontaneous fibrinolysis is an important defence mechanism against downstream infarction 
following occlusive arterial thrombosis. In patients with acute stroke, spontaneous arterial 
recanalization is observed in 17–24% of patients and is strongly related to improved 
functional outcomes. Importantly, ex vivo endogenous fibrinolysis has been shown to be 
significantly impaired in patients with stroke compared to normal volunteers1. Impaired 
endogenous fibrinolysis has also been shown to be marker of recurrent thrombotic risk in 
patients with acute coronary syndrome2 and end-stage renal failure3. 
 
Patients with atrial fibrillation (AF) frequently exhibit impaired endogenous fibrinolysis and 
preliminary data indicate that this state improves after successful restoration of sinus rhythm 
with radiofrequency ablation4. A review of the importance of endogenous fibrinolysis in 
determining clinical outcomes concluded that global assays, assessing proaggregatory and 
fibrinolytic pathways, could aid in identifying impaired fibrinolysis as a potential target for 
pharmacological modulation3.  
 
Currently, there is no available oral pharmacotherapy to favourably modulate fibrinolytic 
status where this is impaired. Beside the use of plasminogen activators to achieve acute 
thrombolysis in the setting of acute myocardial infarction and stroke, pharmacological 
options to manipulate the fibrinolytic state are limited. Our preliminary data indicate that the 
non-vitamin K antagonist oral anticoagulants (NOACs) may enhance endogenous fibrinolysis 
in patients with AF, with significant effect observed only with apixaban4. In our pilot data in 
20 patients, apixaban enhanced endogenous fibrinolysis, evidenced by a significant reduction 
in endogenous fibrinolysis time. However, it is noteworthy that with all NOACs, there was a 
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trend to favourably enhancing endogenous fibrinolysis and perhaps if the sample size had 
been sufficiently large, a significant effect may have been observed. Neither warfarin, nor 
aspirin or clopidogrel, have been shown to enhance endogenous fibrinolysis.  
 
Nevertheless, the impact of pharmacotherapy on the effectiveness of the spontaneous 
endogenous fibrinolytic pathway has been difficult to measure, due to lack of available 
techniques. Factorial assays such as plasminogen activator inhibitor 1, tissue plasminogen 
activator and thrombin activatable fibrinolysis inhibitor cannot provide a reflection of the 
overall state of endogenous fibrinolysis3. There are currently 2 point-of-care techniques that 
provide a global assessment of thrombus formation and fibrinolysis, namely 
thromboelastography (TEG or ROTEM), which uses citrated or whole blood, and the Global 
Thrombosis Test (GTT), using non-anticoagulated blood. The determinants of the results of 
these global tests of fibrinolysis are the thrombus properties (clot strength, determined by the 
thickness, density, and pore size of fibrin strands) and the rate of fibrinolysis.  
 
We hypothesised that there was beneficial effect of apixaban on endogenous fibrinolysis in 
patients with NVAF.  To test this hypothesis, we performed a cross sectional study of NVAF 
patients treated with apixaban, warfarin or aspirin.  Second, we assessed the impact of 
initiating apixaban. 
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Methods 
 
 
We conducted a prospective, observational (non-randomised) study in 200 stable out-patients 
with non-valvular atrial fibrillation (NVAF), approved by the National Research Ethics 
Service and the UK Health Research Authority (ClinicalTrials.gov identifier: 
NCT03199521). All subjects gave written informed consent and the study was conducted in 
accordance with the Declaration of Helsinki and Good Clinical Practice. 
 
The study comprised 2 arms; a longitudinal arm (n=80) and a cross-sectional arm (n=180), 
with 60 patients on apixaban taking part in both. In the prospective longitudinal study, 80 
patients with newly diagnosed NVAF were recruited, who were scheduled to start 
anticoagulation with apixaban for thromboprophylaxis of stroke and systemic embolism and 
who were studied before and during apixaban treatment. In the cross-sectional study, 180 
patients with known NVAF already established on treatment with one of aspirin (n=60), 
warfarin (n=60) or apixaban (n=60) for thromboprophylaxis of stroke and systemic 
embolism, were studied in an observational study, where drug allocation was by physician 
choice, and not randomised.   
 
The following exclusion criteria were applied: age <18 years; significant hepatic or renal 
impairment likely to cause a bleeding diathesis; patients taking antiplatelet or anticoagulant 
therapy (except for patients taking part in the cross-sectional study), systemic steroids or 
immunosuppression; known active malignancy; bleeding diathesis; blood dyscrasia (platelets 
<70 x109/L, haemoglobin <80g/L, international normalized ratio [INR] >1.4; activated partial 
thromboplastin time [aPTT] more than twice upper limit of normal; leukocyte count 
<3.5x109/L, neutrophil count <1x109/L); active alcohol or substance abuse; those involved in 
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another investigational trial of a medicine or medical device; those unable or unwilling to 
provide consent.  
 
Antithrombotic therapy 
The choice of oral antithrombotic therapy was decided by the clinical care team. Apixaban 
was given at a dose of 5mg b.i.d. (or 2.5 mg b.i.d. in patients with two or more of the 
following: age ≥80 years, weight ≤60 kg, serum creatinine ≥133 μmol/L). In the longitudinal 
study, blood samples were taken before (i.e. non-anticoagulated) and after patients were 
established on uninterrupted apixaban treatment for at least 4 weeks. For the cross-sectional 
study, blood samples were obtained after patients had been established on treatment for at 
least 4 weeks. Patients taking warfarin were tested after at least three previous consecutive 
INR readings within the therapeutic range (2.0-3.0). 
 
Blood sampling 
Venous blood samples were obtained from an antecubital vein using an 18-G butterfly 
cannula and a two-syringe technique. The first 5 ml was used for routine blood tests and the 
second 10 ml used for assessment of thrombotic status and apixaban levels measured using 
drug-specific calibrators (anti-Xa [FXa] level). Blood samples were taken 4-6 hours after the 
last dose of apixaban. Fasting was not required.  
 
Assessment of thrombotic status including endogenous fibrinolysis 
 
Global Thrombosis Test 
Thrombotic status was assessed using the point-of-care Global Thrombosis Test (GTT, 
Thromboquest Ltd., London, UK), which assesses overall thrombotic status, including 
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platelet reactivity, coagulation and endogenous (spontaneous) thrombolysis. which assesses 
both platelet reactivity to high shear stress and endogenous fibrinolysis2 .The test was 
performed on native, non-anticoagulated whole blood within 15 s of withdrawal. The 
instrument assesses firstly the time taken to form an occlusive thrombus under high shear, 
which is a marker of platelet reactivity (occlusion time, OT). Shorter occlusion time 
represents enhanced platelet reactivity. Following the arrest of flow due to the formation of 
an occlusive platelet thrombus crosslinked by fibrin strands. Following a short stabilisation 
period, the instrument records the time required to dissolve the thrombus formed in the first 
phase, through endogenous fibrinolysis, which manifests in restart of flow (lysis time, LT). 
Longer lysis times represent less effective endogenous fibrinolysis. In addition, the GTT 
measures thrombus stability by measuring the number of rebleeds (number of drops, D) after 
OT until the compete occlusion and final arrest of flow. The intra-assay and inter-assay 
coefficients of variation (CV) for OT and LT were assessed in 10 subjects on repeated 
sampling and also running samples in parallel. 
 
Thromboelastography 
Venous blood was also assessed with thromboelastography (TEG 5000 Hemostasis Analyser 
System, Haemonetics, Watford, UK). Two tests were performed in parallel for each patient, 
one using non-citrated whole blood tested immediately after withdrawal and one using non-
citrated whole blood with the addition of kaolin activator after four minutes, according to the 
manufacturer’s instructions. The TEG assesses platelet-independent clot formation, 
fibrinogen contribution to clot integrity (R, K, A, MA, TMA) as well as the primary 
fibrinolytic potential of the clot (LY30, LY60, CLT) (Table 3). The intra-assay and inter-
assay coefficients of variation (CV) for all TEG parameters were assessed in 10 subjects on 
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repeated sampling and running samples in parallel for the whole blood alone and with kaolin 
activator. 
 
Apixaban (anti-FXa) levels  
In patients taking apixaban, samples were taken for apixaban level at the same time as blood 
draw for thrombotic status assessment. Apixaban level was measured using HemosIL Liquid 
Heparin kit (Werfen UK, Birchwood, Warrington, Cheshire, UK) on ACL TOP500 analyser 
using drug-specific callibrators.  Based on population pharmacokinetics studies on patients 
taking apixaban 5mg b.i.d. for stoke prevention in NVAF, peak and trough levels of apixaban 
(measured as anti-FXa levels) have been reported as 171ng/ml (91-321) and 103ng/ml (41-
230) respectively5. Anti-FXa levels were assessed by an independent investigator blinded to 
GTT and TEG results. 
 
Study endpoints 
The primary endpoint was the change in thrombotic status, in particular endogenous 
fibrinolysis, in response to apixaban in the longitudinal study. The secondary endpoint was a 
comparison of endogenous fibrinolysis in patients established on different antithrombotic 
treatments (apixaban, warfarin, aspirin) in the cross-sectional study. 
 
Sample size and statistical analysis 
Results from our pilot study4 showed a 24% relative reduction in endogenous fibrinolysis 
time with apixaban with a medium effect size (r=0.4, z=2.763, p=0.006). Using a two-tailed t 
test, we calculated that a sample size of 78 patients would be required to detect a 24% 
relative reduction with 90% power based on an effect size of 0.4 and α=0.05 (longitudinal 
study). For the cross-sectional study, it was assumed that endogenous fibrinolysis in patients 
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taking warfarin and aspirin would be similar, based on our earlier pilot showing no change in 
endogenous fibrinolysis in response to warfarin (8). Assuming a one-tailed independent 
group comparison and an effect size of 0.4, a total of 180 patients were required to give 
α=0.05 to achieve 80% power.  
 
Data are presented as mean±standard deviation when normally distributed, or as median 
(interquartile range), when non-normally distributed. Dichotomous variables were compared 
using chi-square test. Paired comparison between groups was evaluated with paired t-test and 
Wilcoxon ranked sum test. The analysis of variance (ANOVA) or Kruskal-Wallis test were 
used to assess differences between groups. To investigate the relationship between the change 
in fibrinolysis in response to apixaban and baseline characteristics, univariate and 
multivariate regression models were used. All variables were analysed using univariate 
regression; clinically relevant parameters and those shown to be significant (p≤0.05) were 
entered into the multivariate model. In a post hoc analysis, the model’s assumptions were 
tested and the residuals were normally distributed. Regression models were used to illustrate 
the linear prediction between change in LT (D LT) and baseline LT. Correlations were 
analysed using Pearson’s and Spearman’s methods. Analyses were performed with Stata 
version 15.1 (StataCorp, College Station, TX, USA). 
 
 
 
Results 
 
 
 
Between June 2017 and May 2018, 270 patients were screened and 200 patients recruited. 
Clinical characteristics of patients in the longitudinal study are presented in Table 1 and those 
in the cross-sectional study in Table 2. For the GTT, the intra-assay CV for OT was 6% and 
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for LT 8%, and the inter-assay CV was 7% for OT and 9% for LT. The average intra-assay 
CV for TEG was 22% using native blood and 20% for native blood with kaolin. 
 
Effect of apixaban on thrombotic status including endogenous fibrinolysis 
Distributions of OT and LT pre- and during apixaban treatment are shown in Figure 1. 
Compared to baseline, apixaban significantly prolonged OT [361±112 vs. 463±124 sec, 
p<0.0001]. The number of drops (D) did not change in response to apixaban treatment [2.5±1.7 
vs. 3.1±1.6, p=0.173]. There was moderate inverse correlation between the change in OT in 
response to apixaban (DOT) and baseline OT (r= -0.4, p=0.0002).   
Compared to baseline, LT on apixaban was significantly shorter (2204[1779-2738] vs. 
1882[1607-2374] sec, p=0.0003). There was no correlation between baseline OT and baseline 
LT (p=0.740) or between on-treatment OT and on-treatment LT (p=0.241).  
 
Apixaban did not alter TEG indices, except for a small reduction in the rate of clot formation 
with kaolin (68.4º vs. 67º, p=0.026) (Tables 3 and 4).  
 
Baseline OT and LT did not correlate with any of the baseline TEG indices with or without 
kaolin. In particular, baseline fibrinolysis assessment (LT) with the GTT did not correlate with 
any of the baseline TEG indices of fibrinolysis (LY30, LY60 and CLT).  On-treatment OT did 
not correlate with any on-treatment TEG indices. There was a significant correlation between 
DOT and the change in reaction time (R) with kaolin in response to apixaban (r=0.54, 
p<0.0001). There was a weak correlation between on-treatment LT in GTT correlated with clot 
lysis time (CLT) in the TEG (r=0.25, p=0.022). There was weak correlation between DLT and 
the change in kaolin CLT (DCLT) in response to apixaban (r=0.28, p=0.02). 
 
 14 
Magnitude of effect of apixaban in relation to baseline fibrinolysis 
The change in LT in response to apixaban (DLT) correlated closely with baseline LT (r=0.77, 
p<0.0001). The magnitude of effect of apixaban on reducing LT was greatest in those with 
the longest LT at baseline (Figure 2). Patients on apixaban were grouped into quartiles based 
on baseline LT to assess the magnitude of change in LT with apixaban (Table 1). The DLT 
between the four groups was significantly different (p<0.0001).  
 
Cross-sectional comparisons of apixaban, warfarin and aspirin 
Measures of thrombotic status assessed with GTT and TEG are shown in Table 5. LT was 
significantly lower in patients taking apixaban than other medications. From the TEG indices, 
only native CLT was significantly lower in the apixaban group compared to patients on 
warfarin and aspirin. Multivariable regression models were applied to account for baseline 
differences in the three groups. After accounting for these variables (Table 2) both OT and 
LT remained significantly different between the apixaban and the warfarin arms (p<0.0001). 
 
 
Relationship of thrombotic effect to apixaban levels 
Apixaban levels in patients taking 5mg b.i.d. was  Cmax 152.9 ng/ml (32.9-317.9 ng/ml), and 
in patients taking the 2.5mg b.i.d. dose was Cmax 125.85 ng/ml (40.6-344.6 ng/ml). Apixaban 
levels correlated weakly with OT on apixaban (r=0.27, p=0.022) but not with LT. 
There were no significant relationships between apixaban levels and TEG parameters. 
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DISCUSSION 
 
In this study, our principal findings are as follow: (i) Apixaban significantly improved 
endogenous fibrinolysis, and the effect of apixaban was greatest in those patients with the 
longest lysis time at baseline; and (ii) In comparison to patients on warfarin or aspirin, 
patients taking apixaban exhibited more rapid (more effective) endogenous fibrinolysis. 
 
These observations may have clinical relevance, given that effectiveness of endogenous 
fibrinolysis is an important determinant of the clinical outcome of a thrombotic stimulus. 
Whether apixaban may confer additional thrombotic risk reduction in NVAF patients who 
have impaired fibrinolysis, compared to warfarin, requires further study. Importantly, the 
finding that apixaban-treated patients exhibit more favourable fibrinolysis profiles than those 
taking warfarin or aspirin does not mean that apixaban by itself exhibits a more favourable 
fibrinolysis profile as compared to aspirin and warfarin.  
 
In our current study, 23% of patients with NVAF had significantly prolonged lysis time 
before the start of anticoagulation (defined as baseline LT>3000 sec, based on prior data)3. 
Such impaired endogenous fibrinolysis in patients with acute coronary syndromes has been 
associated with increased risk of cardiovascular death and recurrent MI2,3,5. Dual antiplatelet 
therapy post-ACS did not appear to reduce LT. The average 15% reduction in fibrinolysis 
time with apixaban seen here is potentially clinically significant, but even greater effect, up to 
48% reduction in LT was seen in those with the most impaired fibrinolysis at baseline. If 
apixaban were to exert similar reduction in LT in patients with ACS, as that observed here in 
NVAF, that would be expected to reduce the risk of MACE in those with prolonged LT at 
baseline. Our observations suggest that further study in controlled trials could investigate 
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whether apixaban may confer additional thrombotic risk reduction in NVAF patients with 
impaired fibrinolysis, compared to warfarin. 
 
The effect of improving fibrinolytic status with apixaban appears not to be simply an 
anticoagulant effect, since patients on apixaban had more rapid fibrinolysis than patients 
therapeutically anticoagulated with warfarin, and there was no relation between apixaban levels 
and LT. Apixaban levels in our study were similar to those previously reported5 and are known 
to correlate closely with anti-FXa activity. In the ARISTOTLE trial, apixaban was as effective 
as warfarin in reducing the risk of ischaemic stroke and systemic embolism in NVAF, whilst 
the AVERROES study showed that apixaban was superior to aspirin6. Both ARISTOTLE and 
AVERROES suggest a greater benefit of apixaban, compared to warfarin, in reducing 
ischaemic stroke and systemic embolism in patients with CHADS2 score ³3 than in patients 
with lower CHADS2 scores, suggesting apixaban may have additional advantages in the 
highest risk patients. Although in the ARISTOTLE trial comparing apixaban with warfarin in 
NVAF, the secondary endpoint of combined ischaemic or uncertain type (not clearly 
haemorrhagic or ischemic) stroke was non-significantly different with both anticoagulants7, a 
subgroup analysis of patients with previous stroke or TIA showed the rate of stroke or systemic 
embolism was significantly lower with apixaban than with warfarin, suggesting that the 
absolute benefits of apixaban might be even greater in high-risk patients8. In the largest real-
world retrospective analysis of ~77,000 patients with NVAF, apixaban use was associated with 
significantly lower risk of stroke and systemic embolism than warfarin9.  
 
Apixaban is a direct inhibitor of free and clot- or prothrombinase-bound FXa and, thereby, 
prevents thrombin generation. Thrombin is not only a key protein in fibrin clot formation, but 
also the most potent activator of platelet aggregation in vivo10 and an important determinant 
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of the strength and stability of the fibrin clot and its resistance to fibrinolysis11. Apart from 
reduced thrombin generation, FXa inhibition with apixaban might also impact platelet 
haemostasis by blocking the direct effects of FXa via protease activator receptor signalling10. 
Nevertheless, studies assessing the effect of FX inhibition on platelet reactivity are few, but 
appear to show consistency in reduction of tissue-factor/platelet-dependent thrombin 
generation and thrombus formation. Blood spiked with rivaroxaban ex vivo showed reduced 
platelet aggregation induced by tissue factor and to a lesser extent induced by thrombin12,13. 
Even at the very low dose of 2.5 mg b.i.d., rivaroxaban reduced platelet-dependent thrombin 
generation and coagulation-dependent thrombus-formation in patients treated with aspirin 
plus P2Y12 inhibitor, whereas pure platelet-dependent thrombus formation was not affected14. 
Indeed, FXa inhibition appears to have no significant effect on platelets14 including in 
response to adenosine diphosphate, collagen, thrombin receptor-activating peptide or 
arachidonic acid15. Apixaban may therefore favourably enhance endogenous fibrinolysis 
through reduction in platelet-dependent and non-platelet dependent thrombin generation, 
which directly impact on the structure and stability of the thrombus and its resistance to 
fibrinolysis. 
 
The benefit of apixaban on endogenous fibrinolysis was only observed with the Global 
Thrombosis Test and not with TEG. The fundamental difference between these techniques is 
that the GTT employs high shear to stimulate thrombus formation resulting in platelet 
activation and thrombin generation, whereas TEG is a haemostatic assay that measures the 
global viscoelastic properties of whole blood clot formation under low shear. This results in 
significant differences in the clot formed and therefore also in what the “lysis” assays 
measure. The GTT assesses the lysis and stability of a platelet thrombus, whereas in the TEG 
it reflects clot lysis. The GTT is particularly well-adapted to investigate the role of thrombin 
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inhibitors such as NOACs, primarily because thrombin generation from shear-activated 
platelets and fibrin stabilization of the initial platelet aggregates play a major role in 
determining the measured occlusion time3, whereas platelet-dependent thrombin generation is 
much less likely at the low shear rates in the TEG.  
 
Nevertheless, the effect of NOACs on TEG parameters is contentious. Whilst some small 
studies reported that apixaban had minimal effect on TEG parameters, and that for the 
patients on apixaban, mean R value was within reference range representative of a normal 
population16, others have shown that spiking of blood with apixaban in vitro increased R time 
and time to maximal thrombus growth and coagulation17, prolonged clotting time and time to 
maximum velocity18. In the largest study assessing patients with NVAF with TEG, patients 
taking NOAC developed clot that was quicker to lyse than patients taking warfarin, and the 
rate of clot dissolution was faster in those on apixaban than in rivaroxaban, with 11 of 16 
TEG indices showing a difference between those on aspirin, warfarin or a NOAC19. 
 
Clinical implications 
Our finding that that apixaban significantly improves endogenous fibrinolysis, particularly in 
patients with the longest lysis time at baseline, is significant and may be clinically important. 
The current data indicate that apixaban may have additional advantages over VKA or aspirin 
in patients with impaired endogenous fibrinolysis, although since we did not assess patients 
pre- and post-VKA or aspirin, we cannot be sure of the relative effects of apixaban on 
fibrinolysis compared to VKA or aspirin.  
Our findings support the signals from clinical trials, showing that apixaban (rather than VKA 
or aspirin) may have additional advantages in high risk patients. Our data suggest that patients 
with impaired fibrinolysis may benefit more from apixaban to improve fibrinolysis, than 
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warfarin. Future studies are required to confirm whether patients with NVAF and impaired 
fibrinolysis are at increased risk of ischaemic stroke and systemic embolism, than those with 
effective fibrinolysis. If this is confirmed in large prospective studies, then patients with NVAF 
and impaired fibrinolysis may gain additional benefits from treatment with apixaban to 
favourably modulate endogenous fibrinolysis, than from VKA or aspirin. 
Whether enhancing endogenous fibrinolysis with apixaban when this is impaired in patients 
with NVAF or even in acute coronary syndromes, can translate into a reduction in ischaemic 
events, and whether patients with prolonged LT derive greater benefit from apixaban than 
warfarin or other NOAC, requires further study.   
 
Limitations 
The main limitations of our study are the non-randomized, observational study design and the 
relatively small number of participants. The baseline LT in patients subsequently treated with 
apixaban was not uniform and therefore a greater effect of apixaban on LT may have been 
observed had we included more patients with impaired fibrinolysis at baseline. In the cross-
sectional study, there were differences in clinical characteristics between the groups. Since 
fibrinolysis was not assessed before aspirin or warfarin treatment, we do not know the 
absolute magnitude of effect of these drugs on fibrinolysis, which may confound conclusion 
drawn about the observed shorter LT in patients on apixaban than on warfarin or aspirin. 
However, in contemporary clinical practice, few patients in the U.K. with NVAF are being 
started on VKA and therefore it would not have been logistically easy to compare patients 
pre- and post-VKA. Furthermore, whilst compliance was assessed in the apixaban and 
warfarin arms, it was not assessed in patients taking aspirin. 
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In conclusion, apixaban enhances endogenous fibrinolysis, with maximal effect in those with 
impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable 
fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer 
additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared 
to warfarin, merits further study. 
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 Table 1. Baseline clinical characteristics of patients in longitudinal study 
 Whole group 
 
 
(n=80) 
Baseline  
LT 
 0-1500 
(n=9) 
Baseline  
LT  
1501-3000 
(n=53) 
Baseline  
LT  
3001-4500 
(n=11) 
Baseline  
LT  
4501-6000 
(n=7) 
P 
Value 
Age (yrs) 69.5±13.6 70.2±11.7 69.0±15.0 67.3±11.6 76.0±7.0 0.675 
Male 43(54) 2(22) 33(62) 6(55) 2(29) 0.074 
Weight (kg) 83.28±26.64 67.57±19.61 83.39±25.78 95.57±35.46 83.31±18.11 0.211 
Height (cm) 169.00±14.21 163.77±9.47 172.00±11.35 160.90±25.79 165.71±7.86 0.085 
BMI 27.93±6.50 24.80±5.25 27.68±6.73 30.31±5.96 30.00±6.01 0.819 
Current smoker 5(6.3) 1(11) 3(5.6) 1(9) 0(0) 0.798 
AF type       
     Paroxysmal 71(88.8) 7(78) 47(89) 10(90) 7(100) 0.567 
     Persistent 9(11.2) 2(22) 6(11) 1(10) 0(0) 0.512 
Hypertension 48(60) 4(44) 30(56) 9(82) 5(71) 0.293 
Diabetes mellitus 11(13.8) 2(22) 7(13) 2(18) 0(0) 0.603 
Hyperlipidemia 29(36.3) 3(33) 20(38) 5(45) 1(14) 0.583 
Prior CAD 5(6.25) 0(0) 4(7.5) 1(9) 0(00 0.712 
Prior MI 2(2.5) 0(0) 1(2) 1(9) 0(0) 0.484 
Prior PCI 2(2.5) 0(0) 2(3.7) 0(0) 0(0) 0.790 
Renal impairment 3(3.8) 1(11) 2(3.7) 0(0) 0(0) 0.562 
Prior major bleeding 2(2.5) 0(0) 2(3.75) 0(0) 0(0) 0.790 
Prior CVA 3(3.8) 0(0) 3(5.5) 0(0) 0(0) 0.662 
LV impairment       
         None 72(90) 7(77) 47(89) 11(100) 9(100) 0.308 
         Mild 5(6) 1(11) 3(5.5) 0(0) 0(0) 0.636 
         Moderate 2(2.5) 1(11) 1(1.8) 0(0) 0(0) 0.350 
          Severe 1(1.5) 0(0) 2(3.7) 0(0) 0(0) 0.790 
CHA2DS2VASC score 3[1-4] 3[2-3] 2[1-4] 3[2-3] 3[2-3] 0.193 
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HASBLED score 1[1-1] 1[1-1] 1[1-1] 1[0-1] 1[1-2] 0.128 
Concomitant medication       
       Statin 29(36) 4(44) 20(38) 4(36) 1(14) 0.621 
       Beta blocker 21(26) 1(11) 14(26) 5(45) 1(14) 0.298 
       CCB blocker 23(28.75) 2(22) 12(23) 5(45) 4(57) 0.144 
       PPI 17(21.25) 2(22) 11(21) 2(18) 2(29) 0.960 
       Metformin 6(7.5) 1(11) 4(7.5) 1(9) 0(0) 0.855 
Baseline blood tests       
      Haemoglobin (g/L) 138±19 127±18 139±20 144±9 134±19 0.118 
      Haematocrit (%) 41±5 38±5 41±5 43±3 40±7 0.151 
      Platelet count 
(x109/L) 
257±85 296±76 248±85 249±28 281±141 0.259 
      White cell count 
(x109/L) 
8.7±2.7 7.7±1.8 8.8±2.4 8.4±3.2 9.1±5.6 0.583 
      eGFR 72±16 74±21 71±16 77±14 65±11 0.261 
      Fibrinogen (g/L) 4.5±1.5 3.6±0.5 4.4±1.5 4.8±0.9 5.8±1.7 0.122 
      PT (sec) 12.0±1.4 11.5±1.3 12.0±1.4 12.1±1.7 11.5±0.9 0.748 
      aPTT (sec) 28.6±3.3 28.6±4.0 28.0±2.2 31.0±6.2 29.2±3.0 0.411 
      CRP (mg/L) 4.8±6.6 2.3±2.2 5.4±7.7 3.2±2.8 7±5 0.182 
OT at baseline (sec) 361±112 377±126 360±110 376±109 324±130 0.740 
LT at baseline (sec) 2204 
[1779-2738] 
1425 
[1350-1454] 
2114 
[1800-2347] 
3427 
[3099-3667] 
5166 
[4843-6000] 
<0.001 
OT on treatment (sec) 463±124 501±98.4 452±118 542±151 376±88 0.038 
LT on treatment (sec) 1882 
[1607-2374] 
1367 
[1206-1607] 
1866 
[1631-2312] 
2322 
[1975-3345] 
2707 
[1710-3285] 
<0.001 
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Values are mean±SD or median[IQR] and n(%).  
BMI: body mass index, AF: atrial fibrillation, CAD: coronary artery disease, CCB: calcium 
channel blocker, MI: myocardial infarction, PCI: percutaneous coronary intervention, PPI: 
proton pump inhibitor, CVA: cerebrovascular accident, Renal impairment defined as 
estimated glomerular filtration rate (eGFR)<60; AF type(34); Left ventricular function 
classification: Mild 45-55% ejection fraction, Moderate 35-45% ejection fraction, Severe 
<35% ejection fraction. 
CHA2DS2VASc score in AF and HAS-BLED bleeding risk, please see references (35, 36). 
Normal values: haemoglobin 130-180 g/L in males and 115-165 g/L in females; haematocrit 
40-52% in males and 36-47% in females; platelet count 150-400 x109/L; white cell count 4-
11 x109/L; eGFR >60; fibrinogen 1.8-5.4 g/L; PT 11-13.5 seconds; aPTT 25-35 seconds; C-
reactive protein 0-5 mg/L. 
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Table 2. Baseline clinical characteristics of patients in cross-sectional study 
 
 
 
Whole group 
(n=180) 
Apixaban 
(n=60) 
Warfarin 
(n=60) 
Aspirin 
(n=60) 
P Value 
Age (yrs) 73.8±12.1 69.6±13.4 74.6±9.7 77.1±12.0 0.248 
Male 105(58) 33(55) 35(58) 37(62) 0.636 
Weight (kg) 82.37±21.22 83.70±27.15 83.62±18.01 79.80±17.16 0.573 
Height (cm) 169.48±11.87 168.45±15.68 171.11±8.83 168.88±9.97 0.567 
BMI 28.00±5.60 28.25±7.08 28.13±5.03 27.60±4.35 0.652 
Current smoker 11(6) 5(8) 4(7) 2(3) 0.598 
AF type      
        Paroxysmal 138(76) 54(90) 35(60) 48(80) 0.001 
         Persistent 28(16) 6(10) 12(20) 10(17) 0.115 
Hypertension 122(68) 37(62) 42(70) 43(70) 0.454 
Diabetes mellitus 33(18) 9(15) 12(20) 12(20) 0.716 
Hyperlipidemia 99(55) 26(43) 31(52) 42(70) 0.011 
Prior CAD 44(24) 3(5) 20(33) 21(35) <0.001 
Prior MI 20(11) 2(3) 10(17) 8(13) 0.054 
Prior PCI 15(8) 2(3) 9(15) 4(6) 0.059 
Renal impairment 18(10) 2(3) 7(12) 9(15) 0.090 
Prior major bleeding 7(4) 2(3) 5(8) 0(0) 0.059 
Prior CVA 25(14) 3(5) 11(18) 11(18) 0.051 
Prior LV impairment      
       None 150(83) 54(90) 47(78) 49(82) 0.090 
       Mild 15(8) 3(5) 6(10) 6(10) 0.253 
       Moderate 9(5) 1(2) 6(10) 2(3) 0.147 
       Severe 6(4) 2(3) 1(2) 3(5) 1.000 
CHA2DS2VASC score 3[2-4] 3[1-4] 4[2-5] 4[3-5] 0.945 
HASBLED score 1[1-2] 1[1-1] 1[1-2] 1[1-2] 0.388 
Concomitant medication      
 29 
 
 
 
Values are mean±SD or median[IQR] and n(%).  
BMI: body mass index, AF: atrial fibrillation, CAD: coronary artery disease, CCB: calcium 
channel blocker, MI: myocardial infarction, PCI: percutaneous coronary intervention, PPI: 
proton pump inhibitor, CVA: cerebrovascular accident, Renal impairment defined as 
estimated glomerular filtration rate (eGFR)<60; AF type(34); Left ventricular function 
classification: Mild 45-55% ejection fraction, Moderate 35-45% ejection fraction, Severe 
<35% ejection fraction. 
CHA2DS2VASc score in AF and HAS-BLED bleeding risk, please see references(35, 36).  
Normal values: haemoglobin 130-180 g/L in males and 115-165 g/L in females; haematocrit 
40-52% in males and 36-47% in females; platelet count 150-400 x109/L; white cell count 4-
       Statin 107(59) 25(42) 40(66) 42(70)  0.003 
       Beta blocker 92(51) 15(25) 11(18) 15(25) <0.001 
        CCB 44(24) 18(30) 11(18) 15(25) 0.329 
       PPI 68(38) 13(22) 26(43) 29(48)  0.006 
       Metformin 19(11) 5(8) 7(12) 7(12) 0.790 
Baseline blood tests      
      Haemoglobin (g/L) 134±17 138±18 132±15 133±16 0.428 
      Haematocrit (%) 40±5 41±5 40±4 40±4 0.743 
      Platelet count (x109/L) 227±72 235±55 215±85 229±72 0.052 
   White cell count (x109/L) 7.6±2.0 7.9±2.1 7.1±1.9 7.7±2.0 0.093 
      eGFR 67±16 70±16 66±16 65±17 0.139 
 
      Fibrinogen (g/L) 4.5±1.1 4.4±1.4 4.5±1.0 4.5±0.9 0.402 
      PT (sec) 17.7±9.1 12.0±1.4 29.5±6.7 12.3±2.3 <0.001 
      aPTT (sec) 32.0±7.3 28.3±3.3 38.8±7.3 29.0±5.4 <0.001 
      CRP (mg/L) 5.5±10.6 4.7±6.4 4.0±3.6 7.4±16 0.872 
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11 x109/L; eGFR >60; fibrinogen 1.8-5.4 g/L; PT 11-13.5 seconds; aPTT 25-35 seconds; C-
reactive protein 0-5 mg/L. 
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Table 3. TEG indices  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Reaction Time (R) [min] Measures the time from the start of a sample run until the first 
significant level of detectable clot formation. R reduces in 
hypercoagulable conditions 
Kinetics (K) [min] Measures the time from R until a fixed level of clot strength is 
reached. K is shortened in hypercoagulable conditions.  
Angle  Represents the rate of clot formation and reflects fibrinogen 
activity. Angle relates to K. Both represent the rate of clot 
formation. Angle is larger in hypercoagulable conditions  
Maximum Amplitude 
(MA) [mm] 
Represents whole clot strength and reflects many aspects of clot 
formation including platelet number and function as well as the 
fibrin contribution to clot strength. MA is larger by 
hypercoagulable conditions   
LY30 [%] Represents the percentage of clot which has lysed after 30 
minutes of MA 
LY60 [%] Represents the percentage of clot which has lysed after 60 
minutes of MA 
Time to Maximum 
Amplitude (TMA) [min] 
Measures the time to form maximum clot strength 
Clot Lysis Time (CLT) 
[min] 
Measures the time to 2mm amplitude reduction from MA.  
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Table 4. Difference in GTT and TEG parameters in response to apixaban 
 
  
  
Baseline 
 
(n=80) 
 
Apixaban 
 
(n=80) 
 
P value 
 
 
 
OT (sec) 361±112 463±124 <0.0001 
LT (sec) 2204[1779-2738] 1882[1607-2374] 0.0003 
Reaction Time (R) [min] native 7.8[5.4-11.4] 8.9[6.1-12.2] 0.398 
Reaction Time (R) [min] kaolin 4.2[2.6-5.6] 4.8[3.2-6.3] 0.159 
Kinetics (K) [min] native 3.6[2.6-5.8] 4.2[3.0-7.2] 0.096 
Kinetics (K) [min] kaolin 1.4[1.1-2.2] 1.7[1.4-2.3] 0.113 
Angle [o] native 43.0[39.0-47.0] 42.0[38.0-45.0] 0.552 
Angle [o] kaolin 68.4[65.0-72.0] 67.0[58.0-70.0] 0.026 
Maximum Amplitude (MA) [mm] native 34.5[27.3-48.3] 34.6[29.6-49.8] 0.535 
Maximum Amplitude (MA) [mm] kaolin 21.0[17.8-25.0] 23.3[20.0-25.9] 0.068 
LY30 [%] native 0.1[0.0-3.1] 0.0[0.0-0.4] 0.276 
LY30 [%] kaolin 1.9[0.3-5.4] 0.4[0.0-2.0] 0.066 
LY60 [%] native 1.4[0.0-5.8] 0.5[0.0-3.0] 0.405 
LY60 [%] kaolin 4.2[1.9-9.9] 2.6[1.0-4.6] 0.067 
Time to Maximum Amplitude (TMA) 
[min] native 
34.5[27.3-48.3] 34.6[29.6-49.8] 0.535 
Time to Maximum Amplitude (TMA) 
[min] kaolin 
21.0[17.8-25.0] 23.3[20.0-25.9] 0.068 
Clot Lysis Time (CLT) [min] native 60.6[59.4-61.5] 60.15[57.7-61.2] 0.155 
Clot Lysis Time (CLT) [min] kaolin 60.8[59.5-61.7] 60.8[59.7-61.5] 0.780 
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Table 5. Thrombotic parameters in patients taking apixaban, warfarin and aspirin 
 
OT=occlusion time, LT= lysis time, R=reaction time, K=kinetics, MA=maximal amplitude, 
TMA=time to maximal amplitude, CLT=clot lysis time. 
 
 
 
 
  
Apixaban 
 
 
(n=60) 
 
Warfarin 
 
 
(n=60) 
 
Aspirin 
 
 
(n=60) 
Three  
group 
compari
son 
 
P value 
Apixaban  
vs. 
warfarin 
+aspirin 
 
P value 
Apixaban 
+warfarin 
vs.  
aspirin 
 
P value 
Apixaba
n 
vs. 
Warfari
n 
 
P value 
OT (sec) 463±131 589±154 430±121 0.126 0.054 0.025 <0.0001 
LT (sec) 1850 
[1591-2300] 
2758 
[2014-3502] 
2135 
[1752-2463] 
0.0001 <0.0001 0.465 <0.0001 
R [min] native 8.8[5.7-12.3] 13.0[8.7-17.8] 8.8[6.0-12.2] 0.001 0.059 0.067 0.0007 
R [min] kaolin 4.7[3.0-6.8] 6.5[4.9-10.4] 3.0[2.0-5.0] 0.0001 0.843 0.0002 0.006 
K [min] native 4.4[3.0-7.2] 5.4[3.4-7.5] 4.0[2.6-6.1] 0.076 0.954 0.0517 0.212 
K [min] kaolin 1.7[1.4-2.2] 2.0[1.5-2.7] 1.5[1.2-2.7] 0.152 0.789 0.0367 0.265 
Angle [o] native 45.3[30.7-52.1] 33.0[26.2-47.9] 46.0[33.0-59.0] 0.009 0.793 0.011 0.050 
Angle [o] kaolin 70.0[57.0-69.0] 61.0[47.0-69.0] 67.3[60.0-72.0] 0.152 0.839 0.084 0.265 
MA [mm] native 70.0[64.0-76.0] 69.0[56.0-75.0] 69.0[62.0-75.0] 0.673 0.386 0.830 0.347 
MA [mm] kaolin 76.0[72.0-80.0] 75.0[72.0-79.0] 75.0[73.0-79.0] 0.872 0.632 0.819 0.703 
LY30 [%] native 0.0[0.0-0.9] 0.0[0.0-1.3] 0.0[0.0-1.1] 0.841 0.810 0.744 0.980 
LY30 [%] kaolin 0.4[0.0-2.0] 0.6[0.0-3.9] 1.2[0.3-2.4] 0.872 0.264 0.293 0.520 
LY60 [%] native 0.6[0.0-3.1] 0.5[0.0-5.6] 1.3[0.1-4.7] 0.744 0.598 0.542 0.993 
LY60 [%] kaolin 2.6[1.0-5.0] 3.0[1.0-9.5] 4.2[2.1-5.9] 0.588 0.321 0.388 0.532 
TMA [min] native 35.0[30.0-50.0] 37.0[32.0-49.0] 32.0[26.0-43.0] 0.064 0.874 0.037 0.253 
TMA [min] kaolin 24.0[20.0-26.0] 26.0[22.0-30.0 21.0[16.0-23.0] 0.001 0.798 0.001 0.0511 
CLT [min] native 60.0[45.0-61.0] 61.0[57.0-62.0] 61.0[59.0-61.0] 0.036 0.011 0.100 0.055 
CLT [min] kaolin 61.0[60.0-62.0] 61.0[60.0-62.0] 60.8[60.4-61.4] 0.998 0.956 0.889 0.883 
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Figure 1.  Effect of apixaban on occlusion time and lysis time 
 
(A) Distribution of OT before and after apixaban treatment. (B) Distribution of LT before and 
after apixaban treatment. Apixaban significantly prolonged OT as evidenced by rightward 
shift (reduction in platelet reactivity). LT was significantly reduced as evidenced by leftward 
shift (representing faster lysis).  
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Figure 2.  Effect of apixaban on lysis time according to baseline LT 
 
The effect of apixaban on LT was particularly marked in patients with longest baseline LT. 
* p =0.040, ** p=0.018 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
